Increasing RB1 Expression by Targeting EZH2 in Triple‐Negative Breast Cancer
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Renfei Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Triple Negative Breast Neoplasms, Retinoblastoma Binding Proteins, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Outstanding Youth Science Foundation, Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Loss of RB1 function represents a defining characteristic of triple‐negative breast cancer (TNBC) and is intricately associated with resistance to therapeutic interventions. In this study, we investigate the epigenetic mechanisms governing RB1 expression in TNBC. Employing a combination of bioinformatics analyses and experimental validations, we identified lysine histone methyltransferase EZH2 as a key upstream regulator of RB1 expression. EZH2 primarily mediates trimethylation of lysine 27 on histone H3 as the catalytic subunit of the Polycomb repressive complex 2 (PRC2) complex. Furthermore, our findings demonstrate that pharmacological inhibition of EZH2 leads to a significant upregulation of RB1 expression levels, mediated by enhanced enrichment of the activating histone marker H3K27ac at the RB1 enhancer region, as evidenced by ATAC‐sequencing and ChIP‐qPCR assays. These insights unveil a promising clinical avenue for combating RB1‐mediated drug resistance in TNBC through the strategic integration of epigenetic‐targeting agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- School of Chemistry and Material Science, University of Science and Technology of China, Hefei, China.
- School of Pharmaceutical Science and Technology (SPST), Tianjin University, Tianjin, China.
- College of Pharmacy, Zhejiang University of Technology, Hangzhou, China.
- Hangzhou Institute for Advanced Study (UCAS), Chinese Academy of Sciences, Hangzhou, China.
ORCID-Profile: Renfei Yang, Liyan Fei
Förderung
- Zhejiang Provincial Outstanding Youth Science Foundation
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Yang, R., Fei, L., Xue, Y., Zhang, Y., Hu, Q., Guo, L., Wei, Y., & Wu, Q. (2025). Increasing RB1 Expression by Targeting EZH2 in Triple‐Negative Breast Cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70384
Vancouver
Yang R, Fei L, Xue Y, Zhang Y, Hu Q, Guo L, et al. Increasing RB1 Expression by Targeting EZH2 in Triple‐Negative Breast Cancer. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70384
BibTeX
@article{Yang2025,
author = {Yang, Renfei and Fei, Liyan and Xue, Yingfei and Zhang, Yu and Hu, Qian and Guo, Lu and Wei, Yong and Wu, Qin},
title = {Increasing RB1 Expression by Targeting EZH2 in Triple‐Negative Breast Cancer},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70384}
}
EUVIMED